Apellis Pharmaceuticals announced preliminary U.S. net product revenues of approximately $366 million for the full year 2023 for SYFOVRE secondary to age-related macular degeneration and for EMPAVELI for adults with paroxysmal nocturnal hemoglobinuria.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on APLS:
- Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Apellis Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
- Apellis Pharmaceuticals to Host a Fireside Chat at the Goldman Sachs Healthcare C-Suite Unscripted Conference
- Apellis Pharmaceuticals call volume above normal and directionally bullish
- Apellis price target lowered by $3 at Citi, here’s why
